tetano
Editor, Senior Moderator
PLoS One
. 2021 Oct 5;16(10):e0258229.
doi: 10.1371/journal.pone.0258229. eCollection 2021.
Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study
Seong Hee Kang[SUP] 1 2 [/SUP], Dong-Hyuk Cho[SUP] 3 [/SUP], Jimi Choi[SUP] 4 [/SUP], Soon Koo Baik[SUP] 1 2 [/SUP], Jun Gyo Gwon[SUP] 5 [/SUP], Moon Young Kim[SUP] 1 2 [/SUP]
Affiliations
Abstract
Background/aims: We measured the association between underlying chronic hepatitis B (CHB) and antiviral use with infection rates among patients who underwent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing.
Methods: In total, 204,418 patients who were tested for SARS-CoV-2 between January and June 2020 were included. For each case patient (n = 7,723) with a positive SARS-CoV-2 test, random controls (n = 46,231) were selected from the target population who had been exposed to someone with coronavirus disease 2019 (COVID-19) but had a negative SARS-CoV-2 test result. We merged claim-based data from the Korean National Health Insurance Service database collected. Primary endpoints were SARS-CoV-2 infection and severe clinical outcomes of COVID-19.
Results: The proportion of underlying CHB was lower in COVID-19 positive patients (n = 267, 3.5%) than in COVID-19 negative controls (n = 2482, 5.4%). Underlying CHB was associated with a lower SARS-CoV-2 positivity rate, after adjusting for comorbidities (adjusted odds ratio [aOR] 0.65; 95% confidence interval [CI], 0.57-0.74). Among patients with confirmed COVID-19, underlying CHB tended to confer a 66% greater risk of severe clinical outcomes of COVID-19, although this value was statistically insignificant. Antiviral treatment including tenofovir and entecavir was associated with a reduced SARS-CoV-2 positivity rate (aOR 0.49; 95% CI, 0.37-0.66), while treatment was not associated with severe clinical outcomes of COVID-19.
Conclusions: Underlying CHB and antiviral agents including tenofovir decreased susceptibility to SARS-CoV-2 infection. HBV coinfection did not increase the risk of disease severity or lead to a worse prognosis in COVID-19.
. 2021 Oct 5;16(10):e0258229.
doi: 10.1371/journal.pone.0258229. eCollection 2021.
Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study
Seong Hee Kang[SUP] 1 2 [/SUP], Dong-Hyuk Cho[SUP] 3 [/SUP], Jimi Choi[SUP] 4 [/SUP], Soon Koo Baik[SUP] 1 2 [/SUP], Jun Gyo Gwon[SUP] 5 [/SUP], Moon Young Kim[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34610052
- DOI: 10.1371/journal.pone.0258229
Abstract
Background/aims: We measured the association between underlying chronic hepatitis B (CHB) and antiviral use with infection rates among patients who underwent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing.
Methods: In total, 204,418 patients who were tested for SARS-CoV-2 between January and June 2020 were included. For each case patient (n = 7,723) with a positive SARS-CoV-2 test, random controls (n = 46,231) were selected from the target population who had been exposed to someone with coronavirus disease 2019 (COVID-19) but had a negative SARS-CoV-2 test result. We merged claim-based data from the Korean National Health Insurance Service database collected. Primary endpoints were SARS-CoV-2 infection and severe clinical outcomes of COVID-19.
Results: The proportion of underlying CHB was lower in COVID-19 positive patients (n = 267, 3.5%) than in COVID-19 negative controls (n = 2482, 5.4%). Underlying CHB was associated with a lower SARS-CoV-2 positivity rate, after adjusting for comorbidities (adjusted odds ratio [aOR] 0.65; 95% confidence interval [CI], 0.57-0.74). Among patients with confirmed COVID-19, underlying CHB tended to confer a 66% greater risk of severe clinical outcomes of COVID-19, although this value was statistically insignificant. Antiviral treatment including tenofovir and entecavir was associated with a reduced SARS-CoV-2 positivity rate (aOR 0.49; 95% CI, 0.37-0.66), while treatment was not associated with severe clinical outcomes of COVID-19.
Conclusions: Underlying CHB and antiviral agents including tenofovir decreased susceptibility to SARS-CoV-2 infection. HBV coinfection did not increase the risk of disease severity or lead to a worse prognosis in COVID-19.